Deal Details
Follow-on Offering
Summary
Baird served as Lead Manager on this offering
About
Ra Pharmaceuticals, Inc. (“Ra Pharma” or the “Company”) (NASDAQ: RARX) recently completed an underwritten public offering of 4,600,000 shares of its common stock at a public offering price of $32.50 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 600,000 shares of common stock. The gross proceeds from the offering are expected to be $149.5 million before deducting underwriting discounts, commissions and estimated offering expenses.Ra Pharma is a clinical-stage biopharmaceutical company focused on leading the field of complement biology to bring innovative and accessible therapies to patients with rare diseases. The Company discovers and develops peptides and small molecules to target key components of the complement cascade. Ra Pharma is headquartered in Cambridge, Massachusetts.
CONTACT US TO LEARN MORE
- Date
- July 2019
- Company
- Ra Pharmaceuticals, Inc.
- Transaction
- M&A
- Sectors
- Healthcare
- Target Geography
- North America
Share
